-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

Benzinga·04/09/2026 16:36:09
Listen to the news
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.